AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21047620 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-tailored Internet-based treatment for anxiety disorders over 10 weeks with online therapist guidance.
Number of subjects: 54
Study 21047620 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 54
Study 18331938 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep overbite correction treatment in mesofacial and brachyfacial subjects
Number of subjects: 0
Study 18331938 — intervention group
Group type: COMPARATOR
Intervention: Deep overbite correction treatment
Number of subjects: 0
Study 16552403 — intervention group
Group type: EXPERIMENTAL
Intervention: Supernatant of 3T3-L1 cells
Number of subjects: 0
Study 16552403 — intervention group
Group type: EXPERIMENTAL
Intervention: Supernatant of 3T3-L1 cells treated with HGF siRNA
Number of subjects: 0
Study 16552403 — intervention group
Group type: EXPERIMENTAL
Intervention: Supernatant of 3T3-L1 cells conditioned with pioglitazone
Number of subjects: 0
Study 16552403 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone treatment in patients
Number of subjects: 0
Study 14636839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg three times a day)
Number of subjects: 20
Study 14636839 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 mg three times a day)
Number of subjects: 20
Study 10761354 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20
Study 10761354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8822764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 82
Study 8822764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 1423087 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MP group)
Number of subjects: 50430
Study 1423087 — intervention group
Group type: COMPARATOR
Intervention: Usual care after an initial physical examination (UC group)
Number of subjects: 50430
Study 3917315 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole 30 mg + thyroxine 0.15 mg daily
Number of subjects: 10
Study 3917315 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine 0.15 mg alone
Number of subjects: 10
Study 3917315 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole followed by thyroxine 0.15 mg alone
Number of subjects: 10
Study 31513248 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of adjuvant oxaliplatin-based chemotherapy
Number of subjects: 1313
Study 31513248 — intervention group
Group type: COMPARATOR
Intervention: 6 months of adjuvant oxaliplatin-based chemotherapy
Number of subjects: 1313
Study 31513248 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of adjuvant chemotherapy
Number of subjects: 1313
Study 31513248 — intervention group
Group type: COMPARATOR
Intervention: 6 months of adjuvant chemotherapy
Number of subjects: 1313
Study 31513248 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX (3-month arm)
Number of subjects: 1313
Study 31513248 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 (3-month arm)
Number of subjects: 1313
Study 31513248 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX (6-month arm)
Number of subjects: 1313
Study 31513248 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 (6-month arm)
Number of subjects: 1313
Study 29849515 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based occupational therapy program (6 weeks)
Number of subjects: 21
Study 29849515 — intervention group
Group type: COMPARATOR
Intervention: Usual activities of societies (control group)
Number of subjects: 21
Study 29849515 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in meaningful activities
Number of subjects: 21
Study 26528636 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline galectin‐3 (≥17.8ng/mL)
Number of subjects: 247
Study 26528636 — intervention group
Group type: EXPERIMENTAL
Intervention: Median values of galectin‐3 (13.4ng/mL)
Number of subjects: 247
Study 26528636 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sST2 (≥35.0ng/mL)
Number of subjects: 247
Study 25237670 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform Switching (PS) implants
Number of subjects: 18
Study 25237670 — intervention group
Group type: COMPARATOR
Intervention: Regular Platform (RP) implants
Number of subjects: 18
Study 23348814 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of MenACWY-TT at 12 months of age (ACWY-1 group)
Number of subjects: 349
Study 23348814 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MenACWY-TT at 9 and 12 months (ACWY-2 group)
Number of subjects: 349
Study 23348814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACWY-1 and ACWY-2 groups
Number of subjects: 349
Study 23348814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules (ACWY-1 and ACWY-2)
Number of subjects: 349
Study 20492047 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music for 30 minutes, three times over two days
Number of subjects: 20
Study 20492047 — intervention group
Group type: COMPARATOR
Intervention: Rest periods for 30 minutes, three times over two days (Control)
Number of subjects: 20
Study 18385123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) for paroxysmal AF
Number of subjects: 70
Study 18385123 — intervention group
Group type: COMPARATOR
Intervention: Control group (LVEF > 50%)
Number of subjects: 70
Study 18385123 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI for paroxysmal AF
Number of subjects: 70
Study 16371487 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic medially directed tape
Number of subjects: 22
Study 16371487 — intervention group
Group type: COMPARATOR
Intervention: Placebo vertically directed tape
Number of subjects: 22
Study 16371487 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 22
Study 12843003 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently elevated thrombin generation (measured by plasma prothrombin fragment 1 + 2 levels)
Number of subjects: 319
Study 11176760 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 9
Study 11176760 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (low dose 2.5 mg)
Number of subjects: 9
Study 9625541 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 36
Study 9625541 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 36
Study 7875811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) route for fluid infusion
Number of subjects: 60
Study 7875811 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) route for fluid infusion
Number of subjects: 60
Study 3345044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release theophylline
Number of subjects: 8
Study 3345044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30968604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (Cisplatin-100 mg/m2 q3w x 3)
Number of subjects: 225
Study 30968604 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-paclitaxel (Cisplatin-20 mg/m2; Paclitaxel-30 mg/m2 qw x 7)
Number of subjects: 225
Study 30968604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 225
Study 30968604 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-paclitaxel
Number of subjects: 225
Study 28327892 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 726
Study 25387260 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly testosterone administration (100 mg T enanthate, im injection, n = 5)
Number of subjects: 19
Study 25387260 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly testosterone administration (alternating months of T and placebo, n = 7)
Number of subjects: 19
Study 25387260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 19
Study 24238792 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 52
Study 24238792 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 150 mg
Number of subjects: 52
Study 24238792 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52
Study 24238792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21683023 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 0
Study 19466920 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward stage transition
Number of subjects: 0
Study 19466920 — intervention group
Group type: COMPARATOR
Intervention: No forward stage transition
Number of subjects: 0
Study 16423667 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue echocardiography and cardiac magnetic resonance with delayed gadolinium (Gd) gadopentetate dimeglumine (DTPA) contrast hyperenhancement
Number of subjects: 30
Study 16423667 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 30
Study 15673998 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected homeopathic medicine
Number of subjects: 420
Study 15673998 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by homeopaths
Number of subjects: 420
Study 15673998 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control using self-selected conventional health care
Number of subjects: 420
Study 15673998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 11728348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 11728348 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0
Study 9224465 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey automated visual field testing
Number of subjects: 106
Study 7962336 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 therapy
Number of subjects: 310
Study 7962336 — intervention group
Group type: COMPARATOR
Intervention: TGPO aAb
Number of subjects: 310
Study 31302851 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanxinning Tablet (GXN), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Number of subjects: 160
Study 31302851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Guanxinning simulation tablets, mainly composed of lactose), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Number of subjects: 160
Study 30051690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group training (8 sessions of 90 minutes each, twice a week for 1 month)
Number of subjects: 66
Study 30051690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 26999528 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-profile implant (Zero-P)
Number of subjects: 72
Study 26999528 — intervention group
Group type: COMPARATOR
Intervention: Cages with plate fixation
Number of subjects: 72
Study 23252417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated barefoot running (SBR)
Number of subjects: 15
Study 23252417 — intervention group
Group type: COMPARATOR
Intervention: Shod running
Number of subjects: 15
Study 22397512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality reminders
Number of subjects: 294
Study 22397512 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 294
Study 20187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination etanercept-methotrexate therapy (EM/EM group, n = 111)
Number of subjects: 398
Study 20187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy (EM/E group, n = 111)
Number of subjects: 398
Study 20187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (M/EM group, n = 90)
Number of subjects: 398
Study 20187135 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (M/M group, n = 99)
Number of subjects: 398
Study 20187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination etanercept-methotrexate therapy (EM/EM group)
Number of subjects: 398
Study 20187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy (EM/E group)
Number of subjects: 398
Study 20187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (M/EM group)
Number of subjects: 398
Study 20187135 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (M/M group)
Number of subjects: 398
Study 18576924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral administration of C. aurantium L. extracts and auricular acupressure
Number of subjects: 10
Study 18576924 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of C. aurantium L. extracts
Number of subjects: 10
Study 16011397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking cessation intervention (n = 26)
Number of subjects: 54
Study 16011397 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 54
Study 12183860 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty + Stenting (AS)
Number of subjects: 96
Study 12183860 — intervention group
Group type: COMPARATOR
Intervention: Coronary Bypass Surgery (CABG)
Number of subjects: 96
Study 10365642 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 11
Study 7863967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg) and Warfarin (dosed to an INR of 1.5)
Number of subjects: 0
Study 7863967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Warfarin combination
Number of subjects: 0
Study 7863967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone or Warfarin alone
Number of subjects: 0
Study 1645768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg once a day)
Number of subjects: 0
Study 1645768 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25-100 mg twice a day)
Number of subjects: 0
Study 1645768 — intervention group
Group type: EXPERIMENTAL
Intervention: Office sphygmomanometry measurements
Number of subjects: 0
Study 7294038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium therapy
Number of subjects: 70
Study 7294038 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate plus amikacin sulfate therapy
Number of subjects: 70
Study 7294038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin plus amikacin therapy
Number of subjects: 70
Study 7294038 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate and tobramycin sulfate (substituted for amikacin sulfate)
Number of subjects: 70
Study 30282487 — intervention group
Group type: EXPERIMENTAL
Intervention: Results-based financing
Number of subjects: 3000
Study 30282487 — intervention group
Group type: COMPARATOR
Intervention: Non-results-based financing
Number of subjects: 3000
Study 28853202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 20 mg/kg/d
Number of subjects: 40
Study 26953758 — intervention group
Group type: COMPARATOR
Intervention: 4-day antibiotic therapy (n = 72)
Number of subjects: 129
Study 26953758 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer antibiotic therapy (n = 57)
Number of subjects: 129
Study 25438394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fighting Obesity Campaign
Number of subjects: 2038
Study 23253201 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-skills training intervention consisting of eight parent and four youth sessions targeting parenting skills and parent-youth relational factors.
Number of subjects: 336
Study 23253201 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment condition (control group).
Number of subjects: 336
Study 19841330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 120
Study 19841330 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (MMC)
Number of subjects: 120
Study 17681259 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofield treatments delivered from a short distance for a total of 30 minutes before and after exposure to hydrogen peroxide.
Number of subjects: 24
Study 17681259 — intervention group
Group type: COMPARATOR
Intervention: Control group with no healing intervention.
Number of subjects: 24
Study 16244030 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-volume fluid management (8 mL.kg(‐1).h(‐1))
Number of subjects: 253
Study 16244030 — intervention group
Group type: COMPARATOR
Intervention: Large-volume fluid management (16-18 mL.kg(‐1).h(‐1))
Number of subjects: 253
Study 16244030 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-volume fluid management
Number of subjects: 253
Study 16244030 — intervention group
Group type: COMPARATOR
Intervention: Large-volume fluid management
Number of subjects: 253
Study 11894174 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty (PTCA) with stents
Number of subjects: 136
Study 9527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing daily therapy of 50 mg aspirin and 400 mg dipyridamole
Number of subjects: 154
Study 9527071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame counts < or = 27
Number of subjects: 154
Study 9527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count and stenosis severity
Number of subjects: 154
Study 9527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis severity at 4 weeks
Number of subjects: 154
Study 10150852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cataract and glaucoma surgery using small-incision extracapsular cataract extraction (ECCE) with phacoemulsification (PHACO)
Number of subjects: 0
Study 10150852 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of 5-fluorouracil postoperatively
Number of subjects: 0
Study 10150852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C application in PHACO-ECCE-trabeculectomy
Number of subjects: 0
Study 10150852 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C application
Number of subjects: 0
Study 2214100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural instillation of 1500 mg of tetracycline hydrochloride
Number of subjects: 229
Study 2214100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tetracycline)
Number of subjects: 229
Study 646248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid smoking
Number of subjects: 24
Study 31582314 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G (100 μg BDP, 6 μg FF, and 10 μg G)
Number of subjects: 1155
Study 31582314 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G (200 μg BDP, 6 μg FF, and 10 μg G)
Number of subjects: 1155
Study 31582314 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF (100 μg BDP and 6 μg FF)
Number of subjects: 1155
Study 31582314 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF (200 μg BDP and 6 μg FF)
Number of subjects: 1155
Study 30380770 — intervention group
Group type: EXPERIMENTAL
Intervention: Test breads with varying amounts of sourdough (9-51% of dough weight) and rye (35-48% of flour weight)
Number of subjects: 23
Study 30380770 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat control bread
Number of subjects: 23
Study 27241922 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion hysterectomy after chemo-radiation (Group B)
Number of subjects: 150
Study 27241922 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Group A)
Number of subjects: 150
Study 25293893 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous compression plating (PCCP)
Number of subjects: 121
Study 25293893 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 121
Study 22773165 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg JNJ-37822681 (twice daily for 13 doses)
Number of subjects: 12
Study 22773165 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of JNJ-37822681
Number of subjects: 12
Study 22773165 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of JNJ-37822681
Number of subjects: 12
Study 20605012 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization with ecological sounds
Number of subjects: 0
Study 20605012 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment task for sound rate memory
Number of subjects: 0
Study 20605012 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of event rate vs. duration
Number of subjects: 0
Study 17852440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (rHuEPO) administered at a dose of 450 IU/kg, once weekly, subcutaneously for 12 weeks.
Number of subjects: 60
Study 17852440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (rHuEPO)
Number of subjects: 60
Study 17852440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epoetin alfa)
Number of subjects: 60
Study 16117460 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesis coated oxygenators
Number of subjects: 108
Study 16117460 — intervention group
Group type: COMPARATOR
Intervention: Monolyth Pro oxygenators (Control)
Number of subjects: 108
Study 12743129 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin (DC)
Number of subjects: 1077
Study 12743129 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin (PC)
Number of subjects: 1077
Study 11294130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplement (initial dose of 6 g and maintenance dose of 4 g)
Number of subjects: 53
Study 11294130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 53
Study 11294130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplement and reduced energy intake
Number of subjects: 53
Study 11294130 — intervention group
Group type: COMPARATOR
Intervention: Reduced energy intake (without fibre)
Number of subjects: 53
Study 8872406 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal stimulation (A)
Number of subjects: 65
Study 8872406 — intervention group
Group type: EXPERIMENTAL
Intervention: Liminal stimulation (B)
Number of subjects: 65
Study 8872406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg i.v.) with liminal stimulation (C)
Number of subjects: 65
Study 8872406 — intervention group
Group type: COMPARATOR
Intervention: All groups after completed series of treatments
Number of subjects: 65